Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History CASI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics CASI

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

CASI Pharmaceuticals Inc

CASI
Current price
1.23 USD -0.09 USD (-6.82%)
Last closed 1.36 USD
ISIN US14757U1097
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 20 527 960 USD
Yield for 12 month -67.63 %
1Y
3Y
5Y
10Y
15Y
CASI
21.11.2021 - 28.11.2021

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The company's hematology/oncology assets in pipeline include CNCT19, an autologous CD19 CAR-T investigative product; BI-1206, an novel anti-Fc"RIIB antibody for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. It has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China. Address: 1701-1702, China Central Office Tower 1, Beijing, China, 100025

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

4.00 USD

P/E ratio

Dividend Yield

Financials CASI

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures CASI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+28 537 000 USD

Last Year

+33 879 000 USD

Current Quarter

+6 240 000 USD

Last Quarter

+13 356 000 USD

Current Year

+11 146 000 USD

Last Year

+20 052 000 USD

Current Quarter

+3 619 000 USD

Last Quarter

+3 228 000 USD
EBITDA -38 247 500 USD
Operating Margin TTM -163.99 %
Price to Earnings
Return On Assets TTM -50.88 %
PEG Ratio
Return On Equity TTM -1 094.50 %
Wall Street Target Price 4.00 USD
Revenue TTM 31 368 000 USD
Book Value -0.52 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 83.00 %
Dividend Yield
Gross Profit TTM 12 959 000 USD
Earnings per share -2.54 USD
Diluted Eps TTM -2.54 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -129.05 %

Stock Valuation CASI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 0.86
Price Sales TTM 0.67
Enterprise Value EBITDA 0.069
Price Book MRQ 11.21

Technical indicators CASI

For 52 weeks

1.10 USD 7.67 USD
50 Day MA 1.87 USD
Shares Short Prior Month 16 884
200 Day MA 3.44 USD
Short Ratio 3.07
Shares Short 20 395
Short Percent 0.17 %